REVIEW ARTICLE

Folate Receptor α: A New Target for an Old Enemy?

Katharina Ruf[1], Ursula Hasler-Strub[1]

ABSTRACT

Ovarian cancer remains one of the biggest challenges in daily gynaeco-oncologic practice due to its high morbidity and mortality. Platinum-based chemotherapy regimens have been the mainstay of advanced ovarian cancer treatment for several decades. However, up to 85% of the patients with advanced disease experience recurrence even after optimal treatment. There are few therapeutic options for the platinum-resistant disease. The rise of immunotherapy in oncology is enormous and a great success, unfortunately, ovarian cancer lags behind other tumors. In this article, we present an overview of an interesting possible target both in the detection and therapy of ovarian cancer. Folate receptor α (FRα) seems to be a promising target given that it is mostly expressed in tumor cells rather than in non-malignant tissue and can be found in ovarian cancer. The latest research shows new possibilities in using FRα as a target in positron emission tomography (PET) as a diagnostic target for cancer cells. Currently, despite early failures, there are promising clinical trials ongoing with FRα-targeted antibody-drug conjugate and small molecules.

Keywords: *platinum-resistant ovarian cancer, Folate-receptor α in diagnostics and therapy, FR-α-antibody-drug conjugates*

INTRODUCTION

CURRENT TREATMENT OF NEWLY DIAGNOSED ADVANCED-STAGE OVARIAN CANCER

Approximately 75% of patients have FIGO stage III (a disease that has spread throughout the peritoneal cavity or that involves extraperitoneal lymph nodes) or FIGO stage IV (disease spread to more distant sites) disease at diagnosis.[1] The standard treatment of epithelial ovarian cancer (EOC) usually consists of a combination of surgery and neo-/adjuvant chemotherapy. In the advanced stage, bevacizumab, a monoclonal antibody, is added to chemotherapy and used as maintenance therapy. Recently, PARP-inhibitors in *BRCA*-mutated as well as in *BRCA* wild-type patients are standard therapies.[2–4]

Surgical staging and cytoreduction, followed by adjuvant chemotherapy, is regarded as a standard treatment option for most women with EOC. Optimal cytoreductive surgery, e.g., no macroscopic tumor left, is increasing the likelihood that chemotherapy will result in long-term disease-free survival.[5] Neoadjuvant chemotherapy (NACT) prior to definitive surgery is an alternative option in selected patients.[6]

RELAPSED OVARIAN CANCER

Despite initial therapy, the majority of women with advanced-stage ovarian cancer will, unfortunately, relapse and require further treatment. The likelihood of recurrence depends on many factors, including the stage at initial diagnosis, the success of initial surgical cytoreduction, the velocity of CA-125 decline, and progression-free interval after primary therapy. However, a predictive marker for recurrence has not been prospectively verified.

The management of the relapsed disease is based upon these factors. Women with recurrent EOC should be carefully considered for both secondary cytoreduction and second-line chemotherapy. The relapsed disease varies from isolated tumor sites to peritoneal

carcinomatosis. Extra-abdominal sites of recurrence are uncommon. Most patients with recurrent ovarian cancer are treated with systemic therapy alone. Surgical treatment is foreseen for a selected group of patients (e.g., limited disease and eligible for platinum therapy) and a remaining matter of debate. Study results are conflicting.[7–13] The standard chemotherapy includes carboplatin in combination with either paclitaxel or gemcitabine or pegylated liposomal doxorubicin (PLD), with the option of adding bevacizumab.[14–16]

If ovarian cancer is no longer eligible for platinum-based regimens, only a few therapy options remain. Patients who are not eligible for platinum agents due to hypersensitivity reactions or to platinum-resistance should be offered treatment in clinical trials. Single-agent treatment includes topotecan, PLD, gemcitabine, paclitaxel, or etoposide.[17,18] The addition of bevacizumab can be considered even in patients who were exposed to it in an earlier line.[19]

Despite all efforts and tremendous research, overall survival rates in advanced stage EOC remain poor. Especially in platinum-resistant disease, therapy options are limited. Tumor-targeted drug delivery systems have emerged as a promising strategy in cancer treatment. In recent years, many receptors have been identified as being overexpressed on cancer cells such as human epidermal growth factor receptor 2 (Her-2) in breast cancer or prostate-specific membrane antigen (PSMA) and can be used as oncological targets for individual therapy.[20]

ROLE OF FOLIC ACID IN THE CELL CYCLE

Folic acid is the precursor of the active co-enzyme tetrahydrofolic acid (THF). THF has a central function in single carbon metabolism. THF acts particularly as a supplier of methyl-, methylene- and formyl groups and is involved in the synthesis of purine bases and deoxy-thymidine monophosphate (dTMP), which are essential for DNA replication. Because of its involvement in the synthesis of DNA building blocks, folic acid plays a crucial role, particularly in pregnancy and in rapidly dividing cells (e.g., bone marrow or tumor cells).[21]

Folic acid is essential for the human organism and cannot be produced intrinsically. The recommended daily dose is 200 µg.[22] In view of additional effects, 600 µg was previously recommended for healthy adults for the prevention of atherosclerosis and 800 µg for pregnant women and breastfeeding mothers.

The daily intake of more than 1,000 µg folic acid has no additional health effects.[23]

In embryonic development, folic acid deficiency can cause neural tube defects such as spina bifida or anencephaly.[24] A deficiency of folic acid in adults causes megaloblastic macrocytic anemia. The co-responsibility of folic acid for cell maturation and differentiation is currently widely investigated.

ROLE OF FRα IN PHYSIOLOGY AND PATHOLOGY OF OVARIAN TISSUE

Folate receptors consist of four glycoproteins α-δ (35-40 kDa), encoded by FOL1-4. FRα and FRβ are attached to the cell membrane, whereas FRγ is free soluble.[25] FRα was subsequently found to be a cancer-associated antigen and was first cloned in 1991.[26] FRα is expressed in some non-malignant tissue in lower levels (**Figure 1**), but it is far more often found on tumor tissues making it an interesting target possibility. FRα plays a crucial role in early embryogenesis. Knock-out mice lacking the Folr1 folate receptor showed this through their inability to reproduce due to embryogenesis failure.[27] Supplementation of folic acid is an easy and cost-effective way of preventing neural tube defects and is recommended by all leading obstetric guidelines.

In adult organisms, FRα might have a less important role in healthy tissue due to its limited-expression and less efficient folate uptake compared to other transporters.[28] In pre-clinical models, FRα seems to have a role in cellular migration and


Figure 1. Cancers overexpressing folate receptor α (FRα) and concordant expression of FRα in non-malignant tissues. Adapted from Scaranti et al. 2020.[32]

The labels within the figure read:

- FRα overexpressed in 14–74% of non-small-cell lung cancers
- Moderate levels of FRα expression, typically restricted to the apical surfaces of bronchial epithelial cells, in 75–90% of tissue samples
- FRα overexpressed in 72–100% of mesotheliomas
- No detectable FRα expression in non-malignant pleural tissue samples
- FRα overexpressed in 20–50% of endometrial cancers
- FRα expressed in 0–7% of non-malignant endometrial tissue samples
- FRα overexpressed in 35–68% of triple-negative breast cancers
- FRα overexpressed in 35–68% of triple-negative breast cancers
- FRα overexpressed in 76–89% of epithelial ovarian cancers
- FRα expressed in 0–25% of non-malignant ovarian tissue samples

invasion and is associated with tumor progression.[29] Similarly, FRα-knockdown in ovarian cancer cells results in impaired cell division, migration, and invasion.[30] Levels of FRα expression are different across the multiple subtypes of ovarian cancer from high expression in high-grade serous (76%) to lower expression in clear-cell ovarian cancer (32%).[31]

OPTIONS FOR TARGETING FRα IN ONCOLOGY

Folate receptor α has been considered an interesting target in anti-cancer treatment for several years. This receptor isoform seems to have a minimal physiological role in the adult body and is overexpressed by a variety of different cancer types, mainly ovarian cancer, lung cancer, and triple-negative breast cancer. It is also highly affine for non-physiological substrates such as folic acid, making the development of folic acid conjugates possible. FRα is currently studied in multiple aspects of detecting and targeting tumor cells.

**Figure 2. Clinical applications of FRα.** FRα, folate receptor α; FITC, Fluorescein isothiocyanate; MOv18, MOv18 immunoglobulin E antibody; CAR T cell, chimeric antigen receptor T-cell; BiTE, Bi-specific T-cell engager. Adapted from Scaranti et al.[32]

IMAGING

As described above, surgery remains one of the mainstays of ovarian cancer treatment. Therefore, efforts have been made to make malignant lesions more visible for the surgeon, both pre- and intraoperatively. A promising diagnostic option is the FRα-targeted contrast-enhanced magnetic resonance

imaging (MRI). There have been investigations with breast cancer cell lines and xenograft with promising results.[33] However, these procedures are still under evaluation and not yet readily available. Radiolabelled folate derivatives have also been widely studied. The first results of 111In-diethylene-triaminepentaacetic acid-folate showed promising results in whole-body single-photon emission computed tomography (SPECT) of women with suspicious adnexal masses. The radiotracer was found to concentrate in all malignant lesions with high sensitivity for the detection of malignant lesions when combined with other radiographic methods.[34]

A cheaper and easier approach for imaging FRα was to produce a peptide derivate of etarfolatide conjugated with ^{99m}Tc.[35] (**Figure 2**) This agent showed promising results in pre-clinical studies and is further investigated. Tumor uptake of ^{99m}Tc-etarfolatide has been studied as a predictive marker in platinum-resistant ovarian cancer. A positive uptake was associated with improved median progression-free survival (PFS) when treated with vintafolide (folic acid-desacetylvinblastine) plus pegylated liposomal doxorubicin (PLD) vs. PLD plus placebo. This could be demonstrated in patients with detectable 10-100% FRα expression but not in those with 0% FRα expression.[35,36]

Recently, a study has been published using ^{18}F-AzaFol as a first-in-human folate receptor PET-tracer with a favorable safety profile and dosimetric properties in patients with non-small cell lung cancer.[37] In order to improve the detection of tumor cells intraoperatively, fluorescent probes were linked to folates. A folate-conjugated derivate of fluorescein isothiocyanate (Folate-FITC/ EC17) was successfully tested intraoperatively and lead to the detection and resection of ovarian cancer lesions otherwise not detected. However, auto-fluorescence at certain wavelengths facilitates false-positive outcomes. Therefore, advancing technology could contribute significantly to improving operative results.[38,39]

KEY TRIALS IN TARGETING FRα

Many potential drugs and methods targeting FRα in patients are currently under investigation in several phase II and III trials, including monoclonal antibodies, folate-drug conjugates, small molecules, vaccines, and CAR T cells.

Antibodies

Farletuzumab seemed to be the most promising antibody as it is a fully-humanized IgG1-antibody that targets FRα and exerts its activity against FRα positive cancer cells in several ways. Half-life is approximately 120h, which allows weekly dosing.[40] After encouraging results in phase I and II trials, it failed its primary endpoint of PFS in a phase III trial when

combined, at different doses, with platinum/taxane versus platinum/taxane and placebo in relapsed ovarian cancer. [41]However, in this trial, patients were not stratified by the expression of FRα in tumor tissue, which might be crucial. The previously described ^{18}F-AzaFol PET-tracer could provide an opportunity for a non-invasive way to detect FRα-positive disease.

MOv18 was initially developed as a mouse immunoglobulin G (IgG) antibody, where its radiolabelled form was used to assess the feasibility of radio-immunoscintigraphy. However, IgG-antibodies promote anti-mouse antibodies in humans, which could lead to an anaphylactic reaction. The effects of MOv18 IgG have been evaluated in several early phase clinical trials and proved to be a safe and valuable option to provide images of ovarian cancer lesions. Despite this, further development has not been pursued. [42]To avoid anaphylactic reactions, a new MOv18 immunoglobulin E (IgE) antibody was developed and is currently investigated in phase I clinical trial (NCT 02546921).

Antibody-drug conjugates

Antibody-drug conjugates (ADCs) are very promising and usually well-tolerated treatment options in targeted therapy. They consist of a cytotoxic payload conjugated to an antibody directed against a tumor-associated antigen. ADCs exert their activity by selective binding of the antibody to tumor tissue internalization and lysosomal degradation and release of the cytotoxic payload, leading to cytotoxic cell death.

Mirvetuximab soravtansine is an ADC consisting of the cytotoxic agent, maytansinoid DM4, linked to a humanized anti-FRα-monoclonal antibody; the approximate half-life is 116-139h and is administered intravenously (IV) every 3 weeks. Pre-clinical and early clinical data were promising and prompted the FORWARD I, phase III trial. Patients with FRα-positive platinum-resistant advanced-stage epithelial ovarian, primary peritoneal, or fallopian tube cancers were randomized to receive chemotherapy (paclitaxel, PLD, or topotecan) or mirvetuximab soravtansine. Unfortunately, the trial failed to meet its primary endpoint on PFS. However, pre-planned analysis of the subgroup with high FRα expression revealed a small but significant improvement of PFS favoring the experimental arm. [44]A repeat phase III trial is currently recruiting patients (NCT04209855) using an optimized immuno-histochemical test, measuring both the intensity and location of cellular staining. Multiple early phase clinical trials combining mirvetuximab soravtansine with immunotherapies, other targeted agents, or conventional chemotherapy are currently ongoing. The ADC, MORAb-202, which combines farletuzumab and eribulin, showed potent antitumor activity in cancer cell lines and xenograft models. A phase I trial is currently recruiting (NCT03386942) patients with solid tumors and will be completed in December 2021.

Folate-drug conjugates

A cytotoxic drug is bound to folate via a cleavable linker and is internalized via the FRα receptor via endocytosis and released in the endosome (**Figure 3**).[35,45] A representative of this class is the previously described vintafolide (formerly known as EC145). After promising results in pre-clinical and phase I trials, vintafolide was investigated in the PRECEDENT phase II trial, revealing a benefit when combined with PLD vs. PLD doxorubicin with placebo in platinum-resistant ovarian cancer. However, grade 3 or 4 adverse events were seen in 76% vs. 54% of patients. Furthermore, its short half-life of 20-30 minutes necessitates a 3-times-per-week administration every second week, making it inconvenient for both patients and clinicians.


Figure 3. Advances in targeting the folate receptor in the treatment/imaging of cancers. Mechanism of vintafolide drug-release into the intracellular milieu. The sulfide linker is cleaved by glutathione, the thiolate then undergoes a self-immolative, 1,2-elimination reaction to release the drug DAVLBH. Glu-SH, glutathione; DAVLBH, desacetyl vinblastine monohydrazine. Adapted from Fernández et al. 2018.[43]

Furthermore, a phase III trial (PROCEED) was suspended after a prespecified interim futility analysis revealed a lack of benefit in PFS (NCT 01170650).[35] Vintafolide is also of interest in FRα positive non-small-cell-ling cancer (NSCLC) and has been studied in a phase II trial (TARGET), showing improvement of objective response rate (ORR) and PFS for the combination of docetaxel plus vintafolide vs. single-agent docetaxel or vintafolide.[46] Other agents, such as folate conjugated epothilone, showed no objective responses in phase I/IIa trials and were therefore not further developed, whereas others are currently under investigation.[47,48]

Thymidylate Synthase Inhibitors

Thymidylate Synthase Inhibitors (TSI) is another possible option for targeting the FRα-receptor of ovarian cancer. TSIs are small molecules that inhibit the thymidylate synthase enzyme. This inhibition prevents C5 methylation from deoxyuridine monophosphate (dUMP), thereby inhibiting the synthesis of deoxythymidine monophosphate (dTMP). Representatives of TSI were earlier studied in the therapy of colorectal cancer, known as quinazolide-derivates. One agent of this drug class, called CT900/BGC945/ONX-0801, is currently investigated in a phase I trial (NCT 02360345) in patients with FRα expressing solid tumors and is estimated to be completed in August 2020.[49]

Table 1. Toxicities of FRα- targeted drugs. Adapted from Scaranti et al. 2020.[32]

Drug	Toxicities	Comment
Farletuzumab	Hypersensitivity reaction	Commonly seen in antibodies
Vintafolide	Nausea, fatigue	Similar to chemo-therapy, treatable
Mirvetuximab soravtansine	Keratitis, diarrhea	Sometimes seen in ADC
CT900	Pulmonary toxicity	

CAR T-cell therapy

Chimeric antigen receptor (CAR) T-cell therapy is promising due to the differential expression of FRα-receptor on the membranes of ovarian cancer cells. These T cells have been genetically engineered to produce an artificial T-cell receptor for use in immunotherapy. Chimeric antigen receptors (CARs) are receptor proteins modified to enable T cells to target a specific protein. CAR T cells are engineered to be specific to an antigen expressed on a tumor that is not expressed on healthy cells. Therefore, FRα, with its limited expression in healthy tissue, seems to be an excellent target. Engineered CAR T cells containing an FRα-specific single-chain variable fragment (scFv; MOv19), coupled to the T-cell receptor chain CD3ζ, in combination with a CD137 (4-1BB) costimulatory motif, were successful in inducing tumor regression in pre-clinical models.[50–52] These CAR T cells are being tested in a phase I trial that is currently recruiting patients with ovarian or fallopian tube cancers, or primary peritoneal carcinoma (NCT03585764) in the US with estimated Completion Date in October 2020.

CONCLUSION AND FUTURE PERSPECTIVES

The biological rationale for targeting FRα in cancer treatment appears to be appealing, though not all treatment approaches were successful. This raises the question: did we entirely understand targeting FRα? Using FRα targeted imaging agents is promising in making occult tumor sites visible, and thus improving the pre- and intra-operative planning of an optimal resection. The lack of single-agent activity of some of the known agents, such as farletuzumab or vintafolide, likely reflects the non-oncogenic properties of FRα, which permits cancer cells to grow even when FRα is effectively targeted by the antibody.[53] Mirvetuximab soravtansine showed limited single-agent activity and likely failed to meet their primary endpoint in phase III trial due to insufficient biomarker stratification. Toxicities were generally manageable and quite comparable with other substances of this drug class.[32] Although the available data of phase III trials in targeting FRα may not be successful enough to be used routinely, there are still many promising trials ongoing, which hopefully evolve further knowledge about the substances and where to use it best. For those agents showing single-agent activity, randomized studies of biomarker-stratified cohorts are eagerly awaited, especially in diseases with limited standard treatment options such as platinum-ineligible ovarian cancer.

TAKE-HOME MESSAGES

- Folate receptor α (FRα) overexpression is seen in ovarian, breast, and lung cancer.
- Antibodies, as well as antibody-drug conjugates (ADC), are currently being investigated.
- Lessons have been learned from recent trials to optimize linker technologies in targeting FRα.
- FRα is a promising biomarker in fluorescence, positron emission tomography (PET), and single-photon emission computed tomography (SPECT) imaging.
- There may also be a therapeutic option for radio-nuclides.

Folate Receptor α in Ovarian Cancer

1. Prat J. Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines From the International Federation of Gynecology and Obstetrics (FIGO).Obstet Gynecol. 2015; 126(1): 171–4.
2. Moore K et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018; 379(26): 2495–505.
3. Pujade-Lauraine E et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9): 1274–84.
4. Mirza MR et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016; 375(22): 2154–64.
5. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): S3-Leitlinie Diagnostik TuNm. S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren, Langversion 4.0, 2020, AWMF-Registernummer: 032/035OL [Accessed May 2020]. Available from: https://www.leitlinienprogramm-onkologie.de/leitlinien/ovarialkarzinom/.
6. Vincent L et al. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group. Eur J Surg Oncol. 2020; 46(9): 1689–96.
7. Harter P et al. Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial. Ann Surg Oncol. 2006; 13(12): 1702–10.
8. Coleman RL et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019; 381(20): 1929–39.
9. Andreas Du Bois J et al. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: Final analysis of AGO DESKTOP III/ENGOT-ov20. ASCO20 Virtual Congress; 29–31 May 2020.
10. Rongyu Zang J et al. A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2. ASCO20 Virtual Congress; 29–31 May 2020.
11. Zang RY et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011; 105(7): 890–6.
12. Bommert M et al. When should Surgery be used for Recurrent Ovarian Carcinoma? Clin Oncol (R Coll Radiol). 2018; 30(8): 493–7.
13. Harter P et al. Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer. 2011; 21(2): 289–95.
14. Parmar M et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003; 361(9375): 2099–106.
15. Lawrie TA et al. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer. Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, editor. Cochrane Database of Systematic Reviews. 2013.
16. Pfisterer J et al. Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006; 24(29): 4699–707.
17. Hanker LC et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012; 23(10): 2605–12.
18. Pignata S et al. Treatment of recurrent ovarian cancer. Ann Oncol. 2017; 28: viii51–6.
19. Li J et al. Addition of bevacizumab to chemotherapy in patients with ovarian cancer: a systematic review and meta-analysis of randomized trials. Clin Transl Oncol. 2015; 17(9): 673–83.
20. Fernandez de Larrea C. Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma. ASH 2019; Orlando, FL, USA; 7–10 December 2019. Oral presentation 136.
21. Lucock M. Folic Acid: Nutritional Biochemistry, Molecular Biology, and Role in Disease. Mol Genet Metab. 2000; 71(1–2): 121–38.
22. RICHTLINIE 2008/100/EG DER KOMMISSION vom 28. Oktober 2008 zur Änderung der Richtlinie 90/496/EWG des Rates über die Nährwertkennzeichnung von Lebensmitteln hinsichtlich der empfohlenen Tagesdosen, der Umrechnungsfaktoren für den Energiewert und der Definitionen. Brussel: Amtsblatt der Europäischen Union; 2008.
23. Bailey SW et al. The extremely slow and variable activity of dihydrofolate reductase in human liver and its implications for high folic acid intake. Proceedings of the National Academy of Sciences. 2009; 106(36): 15424–9.
24. Paul C. Folic acid in pregnancy. BJOG: Int J Obstet Gy. 2016; 123(3): 392–392.
25. Quici S et al. Folic Acid-Conjugated Europium Complexes as Luminescent Probes for Selective Targeting of Cancer Cells. J Med Chem. 2015; 58(4): 2003–14.
26. Coney L et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res . 1991 Nov 15;51(22):6125-32.
27. Piedrahita JA et al. Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development. Nat Genet. 1999; 23(2): 228–32.
28. Kelemen LE. The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander? Int. J. Cancer. 2006; 119(2): 243–50.
29. Siu MKY et al. Paradoxical Impact of Two Folate Receptors, FRα and RFC, in Ovarian Cancer: Effect on Cell Proliferation, Invasion and Clinical Outcome. Ling MT, editor. PLoS ONE. 2012; 7(11): e47201.
30. Figini M et al. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther. 2003; 10(12): 1018–25.
31. AOCS Study Group et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. 2014; 111(12): 2297–307.
32. Scaranti M et al. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 2020; 17(6): 349–59.
33. Meier R et al. Breast Cancers: MR Imaging of Folate-Receptor Expression with the Folate-Specific Nanoparticle P1133. Radiology. 2010; 255(2): 527–35.
34. Siegel BA et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J. Nucl. Med. 2003; 44(5): 700–7.
35. Vergote I et al. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Ther Adv Med Oncol. 2015; 7(4): 206–18.
36. Morris RT et al. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). Ann. Oncol. 2014; 25(4): 852–8.
37. Gnesin S et al. Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer. EJNMMI Res. 2020; 10(1): 32.
38. van Dam GM et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med. 2011; 17(10): 1315–9.
39. Tummers QRJG et al. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget. 2016; 7(22): 32144–55.
40. Konner JA et al. Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor α, in Epithelial Ovarian Cancer: a Phase I Study. Clin Cancer Res. 2010; 16(21): 5288–95.
41. Vergote I et al. A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse. J Clin Oncol. 2016; 34(19): 2271–8.
42. van Zanten-Przybysz I et al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int. J. Cancer. 2001; 92(1): 106–14.
43. Fernández M et al. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem. Sci. 2018; 9(4): 790–810.
44. Moore K et al. FORWARD I (GOG 3011): A phase III study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients (pts) with platinum-resistant ovarian cancer (PROC). Ann Oncol. 2019; 30: v403.
45. Vergote IB et al. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 2015; 34(1): 41–52.
46. Hanna N et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017 Oct 20;35(30):3484-3515.
47. Peethambaram PP et al. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015; 33(2): 321–31.
48. Reddy JA et al. Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic. Sci Rep. 2018; 8(1): 8943.
49. Banerji Uea. Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly (ONX-0801)[08.06.2020]. [Accessed August 2020]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT02360345.
50. Neeson P et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther. 2010; 17(9): 1105–16.
51. Kandalaft LE et al. A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med. 2012; 10(1): 157.
52. Song D-G et al. In Vivo Persistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). Cancer Research. 2011; 71(13): 4617–27.
53. Norton N et al. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer. 2020; 6(1): 4.